Sterling commences large-scale production of Nanologica’s silica particles
Using Nanologica's technology, Sterling will produce the large volumes of NLAB Saga chromatography material needed by Yunbo Technology to perform preparative chromatography.
Global CDMO, Sterling Pharma Solutions has started large-scale production of Nanologica’s silica particles. Nanologica is a nanotechnology company specialising in the development of silica for application in drug development and chromatography.
The company recently signed a long-term supply agreement with Chinese company, Yunbo Technology allowing Sterling to begin production.
Using Nanologica's technology, Sterling will produce the large volumes of NLAB Saga chromatography material needed by Yunbo Technology to perform preparative chromatography with the first batch expected to be ready for testing during 2020.
Andreas Bhagwani, CEO of Nanologica said: "Sterling has over 50 years of experience in cGMP manufacturing for the pharmaceutical industry and very strong process knowledge and expertise in production.
“We feel very comfortable about co-operating with them for scaling up production to completely different volumes than what we manufacture at our site in Södertälje.”
Nanologica announced in February 2018 that it will start manufacturing preparatory chromatography media used in pharmaceutical manufacturing to 'purify' peptides, specifically insulin. Vastly greater amounts of silica are used in preparative chromatography than in analytical chromatography, where Nanologica is active today.
The first commercial batch is expected to be delivered by Sterling during 2021.
Sterling Pharma Solutions, which has sites in the UK and the US, is a well-established manufacturer of active substances, materials and products for customers in the pharmaceutical industry.
Kevin Cook, CEO of Sterling Pharma Solutions said: “Sterling is delighted to be working with Nanologica on this exciting and innovative opportunity. Sterling has rich experience in development and scale-up of complex synthesis in a fully cGMP environment.
“The combination of the Nanologica expertise and technology, together with Sterling’s manufacturing expertise, provides the required combination for successful commercialisation.”
Nanologica has assessed the preparative chromatography market and believes there is significant potential for growth. The company is planning to expand its presence and customer base within the field facilitated by the start of large-scale manufacturing and being able to provide larger samples to customers for testing.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.